Soleno Therapeutics Inc.
SLNO
NSC
Sector: Healthcare
Industry: Diagnostics & Research
1.74
USD
0.07
(4.19%)
Optionable: Yes Market Cap: 208 M 90-day average vol: 140,179
Previous close: 1.67 Open: 1.75 Bid: 1.84 Ask: 1.84
52 week range
1.60 13.58
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 0.96 |
PE Ratio (TTM) | -8.90 |
Book Value per Share ($) | 2.51 |
5 Year PE Range | -4.8 , -1.2 |
Returns
7 Day Return | -1.69% | |
1 Month Return | -13.00% | |
3 Month Return | -37.37% | |
1 Year Return | -86.86% | |
3 Year Return | -93.48% | |
5 Year Return | -95.75% | |
YTD Return | -71.71% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 35.95 |
14 Day SMA ($) | 1.87 |
14 Day EMA ($) | 1.84 |
Money Flow Index | 16.59 |
Average True Range | 0.19 |
50 Day SMA ($) | 2.29 |
200 Day SMA ($) | 3.67 |
ADX | 27.31 |
MACD | -0.18 |
Growth
Free Cash Flow QoQ Growth | -27.27% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -14.29% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
SLNO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 3 M | 0 | 387555 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -43788 | -42114 | -28516 | 244455 | 1 M | -1 M | -2 M | -2 M | -2 M | -2 M |
| Gross operating profit | 0 | 3 M | 0 | 34872 | -2 M | -251000 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 1 M | 1 M | 3 M | 8 M | 6 M | 7 M | 7 M | 7 M | 9 M | 11 M |
| Research & development expense | 2 M | 2 M | 2 M | 5 M | 2 M | 3 M | 7 M | 16 M | 23 M | 21 M |
| Operating income | -4 M | -846783 | -5 M | -12 M | -8 M | -10 M | -14 M | -23 M | -32 M | -32 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -22411 | -1965 | -4 M | -4 M | 2 M | -3 M | 2 M | -8 M | 7 M | 1 M |
| Pre-tax Income (EBT) | -6 M | -4 M | -13 M | -16 M | -7 M | -13 M | -12 M | -31 M | -25 M | -31 M |
| Income taxes | 0 | 0 | 0 | 0 | 21700 | -2 M | 0 | 0 | 0 | 0 |
| Net income from total operations | -6 M | -4 M | -13 M | -16 M | -12 M | -15 M | -13 M | -31 M | -25 M | -31 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -6 M | -4 M | -13 M | -16 M | -12 M | -15 M | -13 M | -31 M | -25 M | -31 M |
| Preferred dividends | N/A | N/A | N/A | N/A | 4 M | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -6 M | -4 M | -13 M | -16 M | -10 M | -12 M | -12 M | -31 M | -25 M | -31 M |
| Depreciation | 43788 | 42114 | 28516 | 108228 | 18670 | 2 M | 2 M | 2 M | 2 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -4 M | -804862 | -9 M | -12 M | -8 M | -8 M | -12 M | -21 M | -30 M | -30 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -23.13 | -13.25 | -54.6 | -8.45 | -5.05 | -1.71 | -0.64 | -0.9 | -0.39 | -0.39 |
| Diluted EPS total | -23.13 | -13.25 | -54.6 | -8.45 | -5.05 | -1.71 | -0.64 | -0.9 | -0.39 | -0.39 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today